Search results
Results from the WOW.Com Content Network
The game runs on an engine known as the Akili Selective Stimulus Management engine. [2] EndeavorRx was known as AKL-T01 or Project: EVO ADHD Treatment during its development. [3] On June 15, 2020, it became the first ever video game to be approved by the FDA. It was approved to be used as a treatment for children with ADHD with the age range of ...
Central consequences are agitation, confusion, and hallucinations. An untreated overdose may be fatal, particularly in children. Premortal signs are respiratory depression and cardiac arrest. A specific antagonist is physostigmine which combines a peripheral and a central action. Carbachol can be used to treat atonic bowels and bladder. The ...
Guanfacine, sold under the brand name Tenex (immediate-release) and Intuniv (extended-release) among others, is an oral alpha-2a agonist medication used to treat attention deficit hyperactivity disorder (ADHD) and high blood pressure.
Glu Mobile LLC is an American developer and publisher of mobile games. It was founded as Sorrent in 2001 and acquired Macrospace in 2004. Both companies collectively rebranded as Glu Mobile in 2005.
It's Alive Mobile Games AB! 2001-03-14 One of the first location-based games [2] Worldseekers [3] iOS, Android, Windows PC: Final Boss Editing's Games 2025-04-29 Demo Active. Currently in development. Game merges mobile location-gaming with PC deckbuilding. Xyber Mech [4] SMS: one2tribe 2005-04-20 Was available on Polish GSM network Plus GSM ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
Methylphenidate, sold under the brand names Ritalin (/ ˈ r ɪ t ə l ɪ n / RIT-ə-lin) and Concerta (/ k ə n ˈ s ɜːr t ə / kən-SUR-tə) [citation needed] among others, is a central nervous system (CNS) stimulant indicated in the pharmacotherapy of attention deficit hyperactivity disorder (ADHD) and narcolepsy.
Xanomeline is an agonist that primarily targets the muscarinic acetylcholine receptor family of five muscarinic receptor subtypes, which are designated M 1-M 5. [2] While it binds with near identical affinity to all five of the muscarinic receptor subtypes as measured by displacement of a muscarinic radioligand, the preponderance of evidence suggests that xanomeline acts preferentially in the ...